Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Granted FDA Fast Track Designation for CUE-101 for the Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
October 04, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively...
Cue Biopharma to Present at Two September 2022 Scientific Conferences
September 07, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Doses First Patient in Phase 1 Study of CUE-102 for Wilms’ Tumor 1 (WT1) - expressing cancers
August 22, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Reports Second Quarter 2022 Financial Results
August 04, 2022 16:30 ET
|
Cue Biopharma, Inc.
BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series
July 11, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the JMP Securities Life Sciences Conference
June 13, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, June 13, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the Jefferies Healthcare Conference
June 01, 2022 08:00 ET
|
Cue Biopharma, Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 17:00 ET
|
Cue Biopharma, Inc.
BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and...
Cue Biopharma Receives FDA Acceptance of Investigational New Drug (IND) Application for CUE-102 in Wilms’ Tumor 1 (WT1) - expressing cancers
May 11, 2022 08:00 ET
|
Cue Biopharma, Inc.
Company to initiate Phase 1 dose escalation and expansion trial for the treatment of Wilms’ Tumor 1 (WT1) positive recurrent/metastatic cancersStarting dose of 1 mg/kg expected to reduce time and cost...